Lupin Pharmaceuticals, Inc.: Presented By-Abhishek Pandey 15020241005

LUPIN
Pharmaceuticals,
Inc.
Presented byAbhishek Pandey
15020241005
Submitted toProf. Smita Santoki

Towards Operations Assignment
About Lupin
Established in 1968, by Dr. Deshbandu Gupta
Company named after Lupin flower, which is known for its theraupatic
nature.
First gained reputation as the largest supplier of TB drugs
Today is a leading global player in Anti-TB, Cephalosporins (antiinfectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol
reducing agents) and has a notable presence in the areas of diabetes,
anti-inflammatory and respiratory therapy
For the financial year ended 31st March 2015, Lupin's Consolidated
turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion)
and Rs. 24,032 million (USD 393 million) respectively
World leader as branded generics"
Mission/Vision
Lupin's mission is to become a transnational pharmaceutical company

through the development and introduction of a wide portfolio of
branded and generic products in key markets.
Products
Generics
More than 75 FDA

approved products
ANDAs in following
areasa. cephalosporins
b. Cardiovascular
c. Controlled release
ANDA
d. Paragraph IVs
Specialty
Committed to child
care
Drug - SUPRAX
Dedicated sales
force to call upon
pediatricians
API
leading manufacturer
of cephalosporin
APIs
wide range of ACEinhibitors and
cholesterol reducing
agents
Market Watch
Global Capabilities footprint

Global HQ,
Mumbai
Market Presence
Growth through M&A

2004
Lupin was operating only from India. Its presence to other countries was
through trade partnerships and direct-to-market initiatives
2005
Lupin was the last entrant into US market amongst Indian Pharma majors
2007
acquired Kyowa in 2007 to enter Japanese market
2008
bought Hormosan Pharma GmbH to improve its position in Europe. This has
helped in strenghtening its presence in European markets
Lupin acquired Generic Health to enter into Australian markets
2009
Acquires Multicare Pharma in Philippines to penetrate into SE Asia
2011
Acquires Irom in Japan to break into top 10 generic brands in Japan
Growth through M&A (contd.)

2012
Enters strategic marketing parnership with Sanofi to foray into neurology

(Philipines)
2014
entered into JV with Yoshindo to create YL Biologics. This is to develop its

portfolio in biosimilars
Acquires Laboratories Grin in Mexico to serve Mexico and Latin America
bought Gavis to become the 5th largest pharma company in US
2015
bought 40% stake of Pharma Dynamics in South Africa. This has made it the
4th largest generic company in SA
Buys Medqumica Indstria Farmacutica, Brazil for further penetration in
Latin America
Purchases Biocom, to foray into Russian market
Growth Drivers
Organic
Maximizing current / near
term pipeline
Inorganic
Specialty
Geographic diversification
Operational / Commercial
excellence
Tech Platforms
Pipeline evolution into

Scale
complex generics / specialty
Leveraging our investments
across geographies
Growth strategy
US
Entry through
generic drugs
Expansion
through
strategic
acquisitions
India
Portfolio
expansion
through R&D
in Pune
New therapy
areas
Japan
Entry through
generic drugs
Expansion
through
strategic
acquisitions
Biosimilar
through JV
Europe
Entry through
trade
partners
German
acquisition
helps in
central
distribution
Other
Markets
Establish
trade
partners
Operational Strategy
Vertically Integrated and diversified manufacturing platform
Control over entire supply chain right from earlyintermediates
Ability to manufacture key products from two or more sites
Extensive capabilities in multiple dosage forms solids,semi-solids,
liquids, injectables and more
Consistent Compliance track record
Responsive and agile supply chain
Differentiated market entry approach
Focus on margin enhancement and overhead optimization
Challenges to cater the growing new markets
Latest in Media!
Lupin launches first ever Duloxetine 40mg Delayed-Release
Capsules in the US (September 3rd, 2015)
Pharma major Lupin Limited announced today that its subsidiary Lupin
Pharmaceuticals, Inc. (Lupin) has launched its Duloxetine 40 mg Delayed-Release (DR)
Capsule, which is the first and only generic Duloxetine formulation to become available
in 40 mg dosage strength. Lupin is excited to bring this new strength to market, as it
adds to the currently-available dosing options for greater flexibility of treatment.
Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths - the 20
mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin's generic Duloxetine 40 mg DR
capsules are therefore the first and only capsule available for patients in this dosage
strength.
Cymbalta Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths had annual
U.S sales of approximately USD 1.05 billion (Brand + Generics - IMS MAT June 2015).
Bibliography
http://www.lupinpharmaceuticals.com/
http://www.lupinpharmaceuticals.com/newsroom.htm
http://
articles.economictimes.indiatimes.com/2010-04-30/news/27578338_1_
kamal-k-sharma-lupin-generic-players
http://
www.pharmacytimes.com/publications/supplement/2012/Generic-Sup
plement-2012/LupinPharmaceuticals_2012
http://
old.businessworld.in/news/business/pharma/how-lupin-got-its-mojo-b
ack/379072/page-1.html
http://
www.thehindubusinessline.com/companies/lupin-looks-at-bigticket-allia
Thanks!
Any questions?
You can find me at:
[email protected]

Lupin Pharmaceuticals, Inc.: Presented By-Abhishek Pandey 15020241005

Uploaded by

Copyright:

Available Formats

Lupin Pharmaceuticals, Inc.: Presented By-Abhishek Pandey 15020241005

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Lupin Pharmaceuticals, Inc.: Presented By-Abhishek Pandey 15020241005

Uploaded by

Copyright:

Available Formats

LUPIN

Submitted toProf. Smita Santoki

Established in 1968, by Dr. Deshbandu Gupta

First gained reputation as the largest supplier of TB drugs

World leader as branded generics"

Lupin's mission is to become a transnational pharmaceutical company

More than 75 FDA

Global Capabilities footprint

Growth through M&A

acquired Kyowa in 2007 to enter Japanese market

Acquires Multicare Pharma in Philippines to penetrate into SE Asia

Acquires Irom in Japan to break into top 10 generic brands in Japan

Growth through M&A (contd.)

Enters strategic marketing parnership with Sanofi to foray into neurology

entered into JV with Yoshindo to create YL Biologics. This is to develop its

Pipeline evolution into

You might also like